Specific Immune Reconstitution After Allogeneic Transplantation and Letermovir Prophylaxis
NCT07915505, Not applicable, Completed, University Hospital, Limoges
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Specific Immune Reconstitution After Allogeneic Transplantation and Letermovir Prophylaxis | ClinicalTrials.gov |
| NCT number | NCT07915505 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 50 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University Hospital, Limoges | ClinicalTrials.gov |
| Conditions | Haematopoietic Stem Cell Transplantation, Antivirals, Cytomegalovirus Infections | ClinicalTrials.gov |
| Interventions | Letermovir, Comparator | ClinicalTrials.gov |
| First posted | 2026-11-04 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Viral load of torque teno virus (TTV) in whole blood | Before transplantation (Day -30 to Day -8), Day 20, Month 3, Month 6, and Month 12 after transplantation. | TTV viral load measured in whole blood and reported as copies/mL. | ClinicalTrials.gov |
| Primary | Qualitative and functional assessment of natural killer (NK) cells | Before transplantation (Day -30 to Day -8) and Day 100 after transplantation in patients not receiving letermovir prophylaxis. | Qualitative and functional analysis of NK cells and measurement of CD74 RNA expression. | ClinicalTrials.gov |
| Primary | CMV-specific cellular immune response | Before transplantation (Day -30 to Day -8), Day 20, Month 3, Month 6, and one month after the end of letermovir prophylaxis, as applicable. An additional assessment will be performed one month after CMV reactivation, if applicable. | CMV-specific cellular immune response measured using QuantiFERON-CMV, ELISpot-CMV, and flow cytometry to quantify CMV-specific alpha-beta and gamma-delta T cells, including intracellular cytokine production and PD-1 receptor expression. | ClinicalTrials.gov |
| Primary | CMV-specific IgG concentration in plasma | Before transplantation (Day -30 to Day -8), Day 20, Month 3, Month 6, and one month after the end of letermovir prophylaxis, as applicable. | Quantification of CMV-specific IgG antibodies in plasma. | ClinicalTrials.gov |
| Primary | Time to development of a significant CMV-specific cellular immune response | From before transplantation (Day -30 to Day -8) through Month 12 after transplantation. | Time from transplantation to the first significant CMV-specific cellular immune response, defined by a positive QuantiFERON-CMV or ELISpot-CMV result according to the manufacturer's cut-offs, or detection of a CMV-specific T-cell response by flow cytometry following stimulation with CMV antigens. | ClinicalTrials.gov |
| Primary | Number of participants with CMV infection | From before transplantation (Day -30 to Day -8) through Month 24 after transplantation. | Number of participants with CMV infection, defined by a positive diagnostic test for CMV detection without clinical symptoms. | ClinicalTrials.gov |
| Primary | Number of participants with CMV disease | From before transplantation (Day -30 to Day -8) through Month 24 after transplantation. | Number of participants with CMV disease, defined as CMV infection associated with clinical symptoms and organ involvement. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 5
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)